Publikationen von Sergey Ryazanov

Fokken, C.; Silbern, I.; Shomroni, O.; Pan, K.-T.; Ryazanov, S.; Leonov, A.; Winkler, N.; Urlaub, H.; Griesinger, C.; Becker, D.: Interfering with aggregated α-synuclein in advanced melanoma leads to a major upregulation of MHC class II proteins. Melanoma Research 34 (5), S. 393 - 407 (2024)

Dervişoğlu, R.; Antonschmidt, L.; Nimerovsky, E.; Sant, V.; Kim, M.; Ryazanov, S.; Leonov, A.; Fuentes-Monteverde, J. C.; Wegstroth, M.; Giller, K. et al.; Mathies, G.; Giese, A.; Becker, S.; Griesinger, C.; Andreas, L. B.: Anle138b interaction in α-synuclein aggregates by dynamic nuclear polarization NMR. Methods 214, S. 18 - 27 (2023)

Antonschmidt, L.; Matthes, D.; Dervişoğlu, R.; Frieg, B.; Dienemann, C.; Leonov, A.; Nimerovsky, E.; Sant, V.; Ryazanov, S.; Giese, A. et al.; Schröder, G.; Becker, S.; de Groot, B. L.; Griesinger, C.; Andreas, L. B.: The clinical drug candidate anle138b binds in a cavity of lipidic α-synuclein fibrils. Nature Communications 13, S. 5385 - 5394 (2022)

Kuebler, L.; Buss, S.; Leonov, A.; Ryazanov, S.; Schmidt, F.; Maurer, A.; Weckbecker, D.; Landau, A. M.; Lillethorup, T. P.; Bleher, D. et al.; Saw, R. S.; Pichler, B. J.; Griesinger, C.; Giese, A.; Herfert, C.: [11C]MODAG-001—towards a PET tracer targeting α-synuclein aggregates. European Journal of Nuclear Medicine and Molecular Imaging 48 (6), S. 1759 - 1772 (2021)

Dominguez-Meijide, A.; Vasili, E.; König, A.; Cima-Omori, M.-S.; Ibáñez de Opakua, A.; Leonov, A.; Ryazanov, S.; Zweckstetter, M.; Griesinger, C.; Outeiro, T. F.: Effects of pharmacological modulators of α-synuclein and tau aggregation and internalization. Scientific Reports 10, 12827 (2020)

Maurer, A.; Leonov, A.; Ryazanov, S.; Herfert, K.; Kuebler, L.; Buss, S.; Schmidt, F.; Weckbecker, D.; Linder, R.; Bender, D. et al.; Giese, A.; Pichler, B. J.; Griesinger, C.: ¹¹ C radiolabeling of anle253b: A putative PET tracer for Parkinson's disease that binds to α-synuclein fibrils in vitro and crosses the blood-brain barrier. ChemMedChem 15 (5), S. 411 - 415 (2020)

Camilleri, A.; Ghio, S.; Caruana, M.; Weckbecker, D.; Schmidt, F.; Kamp, F.; Leonov, A.; Ryazanov, S.; Griesinger, C.; Giese, A. et al.; Cauchi, R. J.; Vassallo, N.: Tau-induced mitochondrial membrane perturbation is dependent upon cardiolipin. Biochimica et Biophysica Acta. Biomembranes 1862 (2), 183064 (2020)

Saravanan, M. S.; Ryazanov, S.; Leonov, A.; Nicolai, J.; Praest, P.; Giese, A.; Winter, R.; Khemtemourian, L.; Griesinger, C.; Killian, J. A.: The small molecule inhibitor anle145c thermodynamically traps human islet amyloid peptide in the form of non-cytotoxic oligomers. Scientific Reports 9 (1), 19023 (2019)

Wegrzynowicz, M.; Bar-On, D.; Calo’, L.; Anichtchik, O.; Iovino, M.; Xia, J.; Ryazanov, S.; Leonov, A.; Giese, A.; Dalley, J. W. et al.; Griesinger, C.; Ashery, U.; Spillantini, M. G.: Depopulation of dense α-synuclein aggregates is associated with rescue of dopamine neuron dysfunction and death in a new Parkinson's disease model. Acta Neuropathologica 138 (4), S. 575 - 595 (2019)

Brendel, M.; Deussing, M.; Blume, T.; Kaiser, L.; Probst, F.; Overhoff, F.; Peters, F.; von Ungern-Sternberg, B.; Ryazanov, S.; Leonov, A. et al.; Griesinger, C.; Zwergal, A.; Levin, J.; Bartenstein, P.; Yakushev, I.; Cumming, P.; Boening, G.; Ziegler, S.; Herms, J.; Giese, A.; Rominger, A.: Late-stage Anle138b treatment ameliorates tau pathology and metabolic decline in a mouse model of human Alzheimer's disease tau. Alzheimer's Research and Therapy 11 (1), 67 (2019)

Bartels, M.; Weckbecker, D.; Kuhn, P. H.; Ryazanov, S.; Leonov, A.; Griesinger, C.; Lichtenthaler, S. F.; Bötzel, K.; Giese, A.: Iron-mediated aggregation and toxicity in a novel neuronal cell culture model with inducible alpha-synuclein expression. Scientific Reports 9, 9100 (2019)

Heras‐Garvin, A.; Weckbecker, D.; Ryazanov, S.; Leonov, A.; Griesinger, C.; Giese, A.; Wenning, G. K.; Stefanova, N.: Anle138b modulates α-synuclein oligomerization and prevents motor decline and neurodegeneration in a mouse model of multiple system atrophy. Movement Disorders 34 (2), S. 255 - 263 (2019)

Ghio, S.; Camilleri, A.; Caruana, M.; Ruf, V. C.; Schmidt, F.; Leonov, A.; Ryazanov, S.; Griesinger, C.; Cauchi, R. J.; Kamp, F. et al.; Giese, A.; Vassallo, N.: Cardiolipin promotes pore-forming activity of alpha-synuclein oligomers in mitochondrial membranes. ACS Chemical Neuroscience 10 (8), S. 3815 - 3829 (2019)

Reiner, A. M.; Schmidt, F.; Ryazanov, S.; Leonov, A.; Weckbecker, D.; Deeg, A. A.; Griesinger, C.; Giese, A.; Zinth, W.: Photophysics of diphenyl-pyrazole compounds in solutions and α-synuclein aggregates. Biochimica et Biophysica Acta (BBA) - General Subjects 1862 (4), S. 800 - 807 (2018)

Martinez Hernandez, A.; Urbanke, H.; Gillman, A. L.; Lee, J.; Ryazanov, S.; Agbemenyah, H. Y.; Benito, E.; Jain, G.; Kaurani, L.; Grigorian, G. et al.; Leonov, A.; Rezaei-Ghaleh, N.; Wilken, P.; Arce, F. T.; Wagner, J.; Fuhrman, M.; Caruana, M.; Camilleri, A.; Vassallo, N.; Zweckstetter, M.; Benz, R.; Giese, A.; Schneider, A.; Korte, M.; Lal, R.; Griesinger, C.; Eichele, G.; Fischer, A.: The diphenylpyrazole compound anle138b blocks Aβ channels and rescues disease phenotypes in a mouse model for amyloid pathology. EMBO Molecular Medicine 10 (1), S. 32 - 47 (2018)

Turriani, E.; Lázaro, D. F.; Ryazanov, S.; Leonov, A.; Giese, A.; Schön, M.; Schön, M. P.; Griesinger, C.; Outeiro, T. F.; Arndt-Jovin, D. J. et al.; Becker, D.: Treatment with diphenyl–pyrazole compound anle138b/c reveals that α-synuclein protects melanoma cells from autophagic cell death. Proceedings of the National Academy of Sciences of the United States of America 114 (25), S. E4971 - E4977 (2017)

Draycheva, A.; Bornemann, T.; Ryazanov, S.; Lakomek, N. A.; Wintermeyer, W.: The bacterial SRP receptor, FtsY, is activated on binding to the translocon. Molecular Microbiology 102 (1), S. 152 - 167 (2016)

Fellner, L.; Kuzdas-Wood, D.; Levin, J.; Ryazanov, S.; Leonov, A.; Griesinger, C.; Giese, A.; Wenning, G. K.; Stefanova, N.: Anle138b partly ameliorates motor deficits despite failure of neuroprotection in a model of advanced multiple system atrophy. Frontiers in Neuroscience 10, 99 (2016)

Wagner, J.; Krauss, S.; Shi, S.; Ryazanov, S.; Steffen, J.; Miklitz, C.; Leonov, A.; Kleinknecht, A.; Göricke, B.; Weishaupt, J. H. et al.; Weckbecker, D.; Reiner, A. M.; Zinth, W.; Levin, J.; Ehninger, D.; Remy, S.; Kretzschmar, H. A.; Griesinger, C.; Giese, A.; Fuhrmann, M.: Reducing tau aggregates with anle138b delays disease progression in a mouse model of tauopathies. Acta Neuropathologica 130 (5), S. 619 - 631 (2015)

Deeg, A. A.; Reiner, A. M.; Schmidt, F.; Schueder, F.; Ryazanov, S.; Ruf, V. C.; Giller, K.; Becker, S.; Leonov, A.; Griesinger, C. et al.; Giese, A.; Zinth, W.: Anle138b and related compounds are aggregation specific fluorescence markers and reveal high affinity binding to α-synuclein aggregates. Biochimica et Biophysica Acta-General Subjects 1850 (9), S. 1884 - 1890 (2015)